| Open Document File Size: 833,49 KBShare Result on Facebook
Company AEs / 90 EXECUTIVE SUMMARY Onyx Pharmaceuticals Inc. / SOC System Organ Class SPA / ECOG Eastern Cooperative Oncology Group / Acronym Definition AE / Onyx Pharmaceuticals Inc. / EXECUTIVE SUMMARY Onyx Pharmaceuticals / Inc. / / Country United States / Canada / / Event FDA Phase / / MedicalCondition pyrexia / upper respiratory tract infection / end-stage multiple myeloma / cancer / multiple myeloma / WITH MULTIPLE MYELOMA / disease / headache / bortezomib-resistant tumor / dyspnea / Refractory Multiple Myeloma / neutropenia / nausea / thrombocytopenia / relapsed and refractory disease / peripheral neuropathy / Actively progressing disease / Renal Insufficiency / febrile neutropenia / rare disorder / Relapsed and Refractory Multiple Myeloma / cardiac disease / lymphopenia / atypical infections / diarrhea / Unmet Medical Need Multiple myeloma / thromboembolic disease / CHF congestive heart failure CI / bortezomib-refractory disease / infections / anemia / / Organization Food and Drug Administration / FDA / Independent Review Committee / Administration of Carfilzomib / / Person Multiple Myeloma / More / / Product Velcade / Dexamethasone / bortezomib / New Drug / Velcade® / 003A1 / Carfilzomib / / Technology Pharmacokinetics / hybridization / Transplantation / Pharmacodynamics / apoptosis / /
SocialTag |
ODAC Briefing Document NDA[removed]